IGM Biosciences Stock: Bad News With No Turnaround In Sight
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.
Lupus Foundation of America16d
IGM Biosciences Halts Development of Two Investigational Treatments for People with Autoimmune and Inflammatory Diseases
IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including lupus.
Nasdaq17d
IGM Biosciences Halts 2 Autoimmunity Programs, Reduces Workforce By 73% To Preserve Cash.
both IgM-based bispecific antibody T cell engagers, for autoimmune diseases. Imvotamab or CD20 x CD3 is a bispecific IgM antibody that targets CD20 and CD3 proteins. It has 10 binding units for ...
IGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan Stanley
IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...
Nature15y
New adjuvants for accelerated and enhanced antibody response
By day 28, the titer of specific antibodies ... IgM (Fig. 2). The adjuvant works equally well for all mammalian species tested (mouse, rabbit, goat and swine). A slightly changed version of the ...
Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)
Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company’s ...